Compare BVS & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BVS | STTK |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 929.6M | 792.9M |
| IPO Year | 2016 | 2020 |
| Metric | BVS | STTK |
|---|---|---|
| Price | $13.45 | $6.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $17.60 | $14.67 |
| AVG Volume (30 Days) | 408.8K | ★ 864.5K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 163.46 | 53.02 |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $568,087,000.00 | $1,000,000.00 |
| Revenue This Year | $6.46 | N/A |
| Revenue Next Year | $6.74 | N/A |
| P/E Ratio | $26.91 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.37 | $1.70 |
| 52 Week High | $15.89 | $8.33 |
| Indicator | BVS | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 52.37 | 60.14 |
| Support Level | $13.44 | $6.75 |
| Resistance Level | $14.71 | $7.75 |
| Average True Range (ATR) | 0.44 | 0.39 |
| MACD | 0.04 | 0.12 |
| Stochastic Oscillator | 75.14 | 90.10 |
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.